Enanta Pharmaceuticals, Inc.

NasdaqGS ENTA

Enanta Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -27.63 M

Enanta Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities is USD -27.63 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -113.94% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Enanta Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 198.13 M, a 889.00% change year over year.
  • Enanta Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 20.03 M, a 550.42% change year over year.
  • Enanta Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 3.08 M, a -65.71% change year over year.
  • Enanta Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 8.98 M, a 248.99% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
SV Wall Street
NasdaqGS: ENTA

Enanta Pharmaceuticals, Inc.

CEO Dr. Jay R. Luly Ph.D.
IPO Date March 21, 2013
Location United States
Headquarters 500 Arsenal Street
Employees 145
Sector Health Care
Industries
Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Similar companies

KRON

Kronos Bio, Inc.

USD 1.02

0.00%

MRUS

Merus N.V.

USD 41.65

2.33%

GLUE

Monte Rosa Therapeutics, Inc.

USD 5.99

2.92%

RVMD

Revolution Medicines, Inc.

USD 40.92

0.00%

MLYS

Mineralys Therapeutics, Inc.

USD 10.36

5.07%

EWTX

Edgewise Therapeutics, Inc.

USD 28.42

2.23%

CRNX

Crinetics Pharmaceuticals, Inc.

USD 39.38

3.03%

CGEM

Cullinan Oncology, Inc.

USD 11.25

7.66%

CCCC

C4 Therapeutics, Inc.

USD 3.59

-1.10%

STOK

Stoke Therapeutics, Inc.

USD 10.51

7.03%

DSGN

Design Therapeutics, Inc.

USD 4.94

-1.40%

HOWL

Werewolf Therapeutics, Inc.

USD 1.34

0.00%

INBX

Inhibrx Biosciences, Inc.

USD 12.31

0.57%

IKNA

Ikena Oncology, Inc.

USD 1.50

1.35%

StockViz Staff

January 30, 2025

Any question? Send us an email